MML Investors Services LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 15.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,676 shares of the life sciences company’s stock after acquiring an additional 358 shares during the period. MML Investors Services LLC’s holdings in Illumina were worth $831,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc grew its stake in Illumina by 1.8% in the third quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after purchasing an additional 188,516 shares during the last quarter. Advisors Asset Management Inc. grew its stake in Illumina by 8.3% in the fourth quarter. Advisors Asset Management Inc. now owns 47,268 shares of the life sciences company’s stock valued at $14,177,000 after purchasing an additional 3,609 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Illumina by 11.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 7,085 shares of the life sciences company’s stock valued at $2,125,000 after purchasing an additional 754 shares during the last quarter. Virtus ETF Advisers LLC purchased a new position in Illumina in the fourth quarter valued at about $31,000. Finally, Oregon Public Employees Retirement Fund grew its stake in Illumina by 66,581.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock valued at $35,000 after purchasing an additional 10,546,495 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.
Shares of NASDAQ ILMN opened at $344.00 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. The stock has a market capitalization of $50.57 billion, a price-to-earnings ratio of 60.14, a price-to-earnings-growth ratio of 2.38 and a beta of 1.07. Illumina, Inc. has a fifty-two week low of $268.62 and a fifty-two week high of $372.61.
In related news, SVP Omead Ostadan sold 1,260 shares of Illumina stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $335.03, for a total transaction of $422,137.80. Following the completion of the sale, the senior vice president now owns 11,945 shares of the company’s stock, valued at $4,001,933.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $334.53, for a total value of $1,103,949.00. Following the sale, the director now directly owns 279,216 shares of the company’s stock, valued at approximately $93,406,128.48. The disclosure for this sale can be found here. Insiders have sold 50,291 shares of company stock valued at $15,747,633 in the last ninety days. Corporate insiders own 0.38% of the company’s stock.
ILMN has been the topic of several analyst reports. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Canaccord Genuity reissued a “buy” rating and issued a $350.00 price target (down previously from $360.00) on shares of Illumina in a report on Friday, April 26th. Wolfe Research started coverage on Illumina in a report on Thursday, May 30th. They issued an “outperform” rating for the company. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a report on Tuesday, April 2nd. Finally, OTR Global downgraded Illumina to a “positive” rating in a report on Tuesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $354.35.
WARNING: “Illumina, Inc. (NASDAQ:ILMN) Holdings Raised by MML Investors Services LLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2019/06/15/illumina-inc-nasdaqilmn-holdings-raised-by-mml-investors-services-llc.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: What is a growth and income fund?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.